Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2012/12/003270
CTRI/2012/12/003270
Recruiting
Phase 3

Aqueous vascular endothelial growth factor (VEGF) profile in central retinal vein occlusion (CRVO) and its correlation with clinical features, spectral domain optical coherence tomography(SD OCT), electroretinogram (ERG) and macular integrity assessment (MAIA) - ProCRVO

arayana Nethralaya0 sites30 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
arayana Nethralaya
Enrollment
30
Status
Recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
arayana Nethralaya

Eligibility Criteria

Inclusion Criteria

  • •Inclusion Criteria
  • •Patients with central retinal vein occlusion who are treatment naïve with or without visual loss \< 3 months duration with or without glaucoma
  • •Patients with well controlled DM will be included when the other eye has less than severe non proliferative diabetic retinopathy

Exclusion Criteria

  • •Exclusion Criteria
  • •Ocular intervention within 3 months like intra ocular surgery, intravitreal steroid/anti VEGF injections and previous history of retinal laser treatment.
  • •Neovascular glaucoma
  • •IOP \> 21 mmHg
  • •Ocular inflammatory conditions
  • •Age related macular degeneration

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Association of Vascular Endothelial Growth Factor (VEGF) serum levels And Ankylosing Spondylitis in Egyptian patientsAnkylosing spondylitis
PACTR202210522771809Hossam salaheldin Abdelmohsen Labib70
Recruiting
Not Applicable
Vascular Endothelial Growth Factor, thrombelastography and coagulation in the context of etiology, outcome and clinical course of patients after circulatory arrestI46Cardiac arrest
DRKS00033234BG-Klinikum Unfallkrankenhaus Berlin150
Completed
Not Applicable
Effect of anti-vascular endothelial growth factor (VEGF) drugs in chronic central serous chorioretinopathy (CSC)chronic central serous chorioretinopathy
JPRN-UMIN000014110Kansai medical university takii hospital10
Completed
Not Applicable
The effect of vascular endothelial growth factor taking tube shunt for neovascular glaucomaneovascular glaucoma
JPRN-UMIN000018407Yokohama City university center hospital the department of opthalmology20
Completed
Not Applicable
Anti-vascular endothelial growth factor therapy for ocular diseases of neovascularizatioretinopathy of prematurity neovascular glaucome vasoproliferative tumor choroidal neovascularization
JPRN-UMIN000027243School of Medicine Toho University20